Galectin Therapeutics (GALT) closed at $3.14 on November 6, 2026, up 5.2% from the previous close, on volume of 222,289 shares (30-day average 200,974).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Calendar Call Spread | 16-Oct : 20-Nov-26 5 C | 210 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Thu, 5-Nov 8:00 AM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Thu, 10-Sep 8:00 AM ET)
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Globe Newswire (Fri, 14-Aug 8:00 AM ET)
FDA Alignment Signals Regulatory Clarity for Galectin Therapeutics' Belapectin Phase 3 Program
Market Chameleon (Wed, 24-Jun 7:45 AM ET)
Market Chameleon (Mon, 22-Dec 5:25 AM ET)
GALT Secures $10 Million Lifeline and Gains FDA Alignment on Pivotal Belapectin Trial
Market Chameleon (Fri, 19-Dec 4:24 AM ET)
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Galectin Therapeutics trades on the NASDAQ stock market under the symbol GALT.
As of November 6, 2026, GALT stock price climbed to $3.14 with 222,289 million shares trading.
GALT has a beta of -0.58, meaning it tends to be less sensitive to market movements. GALT has a correlation of 0.01 to the broad based SPY ETF.
GALT has a market cap of $316.67 million. This is considered a Small Cap stock.
In the last 3 years, GALT traded as high as $7.13 and as low as $.73.
The top ETF exchange traded funds that GALT belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.
GALT has underperformed the market in the last year with a return of -43.7%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GALT shares. However, GALT has outperformed the market in the last 3 month and 2 week periods, returning -2.5% and -1.6%, while SPY returned -4.1% and -3.2%, respectively. This indicates GALT has been having a stronger performance recently.
GALT support price is $2.82 and resistance is $3.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GALT shares will trade within this expected range on the day.
